Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity, Reactogenicity and Safety Assessment of the Meningococcal Serogroup C Vaccine Produced by Bio-Manguinhos / FIOCRUZ in Infants, Children and Adolescents

NCT02858570 is registered in ClinicalTrials.gov with The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) as lead sponsor.

NCT NCT02858570
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02858570 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity, Reactogenicity and Safety Assessment of the Meningococcal Serogroup C Vaccine Produced by Bio-Manguinhos / FIOCRUZ in Infants, Children and Adolescents
Lead sponsor
The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Phase
Phase 2/3
Overall status
Unknown status
Start date
September 25, 2018
Completion date
April 30, 2020
Enrollment
1,644 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

serogroup c meningococcal meningitis